Literature DB >> 1674445

Expression of dipeptidyl aminopeptidase IV activity in thyroid carcinoma.

T Kotani1, Y Aratake, Y Ogata, K Umeki, Y Araki, K Hirai, K Kuma, S Ohtaki.   

Abstract

Dipeptidyl aminopeptidase IV activity staining was performed in various thyroid tissues to evaluate this enzyme activity as a thyroid tumor marker. A total of 195 thyroid tissues were tested for their enzyme activity expression. All papillary and follicular carcinomas, 40 cases and 3 cases, respectively, showed enzyme activity, although two other carcinomas, one medullary and one anaplastic, were not stained. Follicular adenoma expressed enzyme activity in 4 of 26 cases. Fifty-two cases with adenomatous goiter, 54 with Graves' disease and 13 with chronic thyroiditis were judged to be negative. Five normal thyroids expressed no activity except for occasional positive staining of capillary endothelia. These data suggest that dipeptidyl aminopeptidase IV activity staining is very useful for pathological diagnosis of thyroid tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674445     DOI: 10.1016/0304-3835(91)90158-e

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

1.  Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.

Authors:  S H Kim; J G Kang; C S Kim; S-H Ihm; M G Choi; H J Yoo; S J Lee
Journal:  J Endocrinol Invest       Date:  2017-11-16       Impact factor: 4.256

2.  Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epithelial cells by cytokines and cAMP-increasing mediators.

Authors:  A Kehlen; B Göhring; J Langner; D Riemann
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

3.  Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.

Authors:  Si Hyoung Kim; Jun Goo Kang; Chul Sik Kim; Sung-Hee Ihm; Moon Gi Choi; Hyung Joon Yoo; Seong Jin Lee
Journal:  Endocrine       Date:  2017-12-28       Impact factor: 3.633

Review 4.  Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma.

Authors:  M D Ringel
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

5.  CD26 (Dipeptidyl Aminopeptidase IV) Expression in Normal and Diseased Human Thyroid Glands.

Authors:  Marcus A. Lima; Valeria A. Gontijo; Fernando C. L. Schmitt
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

6.  Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13.

Authors:  D Riemann; A Kehlen; J Langner
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

7.  Interspecies differences in membrane-associated protease activities of thyrocytes and their relevance for thyroid cancer studies.

Authors:  Eleonore Fröhlich; Elke Maier; Richard Wahl
Journal:  J Exp Clin Cancer Res       Date:  2012-05-16

8.  CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors.

Authors:  Liang Yan; Xiuyun Tian; Chunxiang Ye; Xiaoya Guan; Bin Dong; Min Zhao; Jianhui Wu; Chunyi Hao
Journal:  Onco Targets Ther       Date:  2020-12-08       Impact factor: 4.147

9.  Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26.

Authors:  Murray J Cutler; Erica L Lowthers; Cynthia L Richard; Dagmar M Hajducek; Paul A Spagnuolo; Jonathan Blay
Journal:  BMC Cancer       Date:  2015-11-10       Impact factor: 4.430

Review 10.  CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma.

Authors:  Sohji Nishina; Keisuke Hino
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.